FORTREA HOLDINGS INC (FTRE) competitors & alternatives
Health Care · NASDAQ
FORTREA HOLDINGS INC (FTRE)'s top competitors and alternatives — its most similar public companies — include IQVIA (IQV), Medpace (MEDP), Revvity (RVTY), NUVECTIS PHARMA INC (NVCT), SIMULATIONS PLUS INC (SLP), TYRA BIOSCIENCES INC (TYRA), NEUMORA THERAPEUTICS INC (NMRA), VOR BIOPHARMA INC (VOR), CYTEK BIOSCIENCES INC (CTKB), PRELUDE THERAPEUTICS INC (PRLD), Caris Life Sciences (CAI) and AURA BIOSCIENCES INC (AURA). These are FORTREA HOLDINGS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top FTRE competitors & alternatives
-
IQVIAIQVHealth Care
IQVIA is a global clinical research and healthcare intelligence platform that powers drug development and commercialization with AI-driven insights from 1.2…
$198.52 (as of 2026-07-22) · market cap $33.2B
-
MedpaceMEDPHealth Care
Medpace is a specialized, full-service clinical contract research organization that helps biopharmaceutical and medical device companies accelerate the…
$528.12 (as of 2026-07-22) · market cap $15.0B
-
RevvityRVTYHealth Care
Revvity is a leading health science technology company providing integrated workflows and reagents spanning drug discovery, development, and diagnostic…
$110.54 (as of 2026-07-22) · market cap $12.3B
-
NUVECTIS PHARMA INCNVCTHealth Care
Nuvectis is an early-stage oncology biotech developing NXP900, a novel SRC/YES1 kinase inhibitor designed to overcome drug resistance in solid tumors including…
$19.29 (as of 2026-07-22) · market cap $608M
-
SIMULATIONS PLUS INCSLPHealth Care
Simulations Plus provides advanced modeling and simulation software and services to accelerate drug discovery and clinical development for the life sciences…
$18.25 (as of 2026-07-22) · market cap $368M
-
TYRA BIOSCIENCES INCTYRAHealth Care
Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly…
$30.59 (as of 2026-07-22) · market cap $1.8B
-
NEUMORA THERAPEUTICS INCNMRAHealth Care
Neumora Therapeutics is a clinical-stage biotechnology company developing precision medicine therapies for psychiatric and neurodegenerative brain disorders.
$1.54 (as of 2026-07-22) · market cap $298M
-
VOR BIOPHARMA INCVORHealth Care
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
$19.51 (as of 2026-07-22) · market cap $1.1B
-
CYTEK BIOSCIENCES INCCTKBHealth Care
Cytek Biosciences sells spectral flow cytometry instruments and integrated cell analysis platforms powered by patented Full Spectrum Profiling technology that…
$4.54 (as of 2026-07-22) · market cap $586M
-
PRELUDE THERAPEUTICS INCPRLDHealth Care
An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
$3.92 (as of 2026-07-22) · market cap $313M
-
Caris Life SciencesCAIHealth Care
Caris Life Sciences delivers precision oncology and molecular profiling solutions that help biopharma companies and physicians make treatment decisions through…
$15.38 (as of 2026-07-22) · market cap $4.3B
-
AURA BIOSCIENCES INCAURAHealth Care
Aura Biosciences is a clinical-stage biotech developing precision Viral-like Drug Conjugate (VDC) therapies designed to treat solid tumors while preserving…
$7.01 (as of 2026-07-22) · market cap $725M
Not quite? Describe exactly what you want →
Peers are FORTREA HOLDINGS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: FORTREA HOLDINGS INC (FTRE).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.